Cefepime monitoring in deproteinized human serum and plasma by micellar electrokinetic capillary chromatography and liquid chromatography coupled to mass spectrometry in presence of other drugs is reported. For micellar electrokinetic capillary chromatography, sample preparation comprised dodecylsulfate protein precipitation at pH 4.5 using an increased buffer concentration compared to that of a previous assay and removal of hydrophobic compounds with dichloromethane. This provided robust conditions for cefepime analysis in the presence of sulfamethoxazole and thus enabled its determination in samples of patients that receive co-trimoxazole. The liquid chromatography assay is based upon use of a column with a pentafluorophenyl-propyl modified and multiendcapped stationary phase and the coupling to electrospray ionization with a single quadrupole detector. The performances of both assays with multi-level internal calibration were assessed with calibration and control samples and both assays were determined to be robust. Cefepime levels monitored by micellar electrokinetic capillary chromatography in samples from patients that were treated with cefepime only and with cefepime and co-This article is protected by copyright. All rights reserved. 3 trimoxazole were found to compare well with those obtained by liquid chromatography coupled to mass spectrometry. Cefepime drug levels determined by micellar electrokinetic capillary chromatography could thereby be validated.
more compounds, cefepime levels could not be determined in 50 samples. Many of these sera contained sulfamethoxazole, which is an active ingredient of co-trimoxazole (sulfamethoxazole and trimethoprim). Co-trimoxazole (e.g. Bactrim ®) is an antibiotic formulation that is occasionally used together with cefepime in immunosuppressed patients (e.g. for Pneumocystis jirovecii prophylaxis and cefepime for treatment of neutropenic fever). Sulfamethoxazole could not be separated from cefepime under the used MEKC assay conditions. Hence, analyses had to be repeated without co-trimoxazole (i.e. co-trimoxazole treatment was stopped about 24 h before blood collection for TDM of cefepime). This prompted us to change sample preparation to remove hydrophobic compounds such as sulfamethoxazole and to provide conditions that lead to the separation of cefepime and residual amounts of sulfamethoxazole. Furthermore, an LC-MS assay for cefepime was developed, applied to representative sets of patient samples and used to validate the drug levels determined by MEKC. In this paper, modifications of sample preparation for MEKC, the performance of the MEKC assay with modified sample preparation, the development Journal of Separation Science This article is protected by copyright. All rights reserved. 5 and characterization of the LC-MS assay and the comparison of cefepime levels obtained by MEKC and LC-MS are presented.
Materials and methods

Chemicals, materials and patient samples
Used reagents were of analytical or research grade. Cefepime dihydrochloride monohydrate was obtained from Sandoz Pharmaceuticals (Cham, Switzerland). Ceftazidime pentahydrate, obtained from Glaxo (Greenford, Middlesex, UK) or deuterated cefepime-d3 sulfate from TRC (Toronto, Canada) were used as internal standards. Sulfamethoxazole was from Helvepharm (Schmitten, Switzerland). Sodium acetate, formic acid (98-100%), acetic acid (100%) and Na 2 HPO 4  2 H 2 O were purchased from Merck (Darmstadt, Germany). Na 2 B 4 O 7  10 H 2 O, SDS and ammonium formate were from Fluka (Buchs, Switzerland).
Dichloromethane was obtained from VWR (Schlieren, Switzerland). Bovine serum (adult) was purchased from Sigma (St. Louis, MO, USA) and was used for the preparation of calibration and control samples. Patient samples were provided from the University Hospital Bern, Switzerland. The analyses were performed within the context of QC. Analysis of patient samples was approved by the local ethical committee (KEK-BE 035/2014, SNCTP 801).
MEKC assay with dichloromethane removal of interferences
Solutions, calibrators and controls Journal of Separation Science
This article is protected by copyright. All rights reserved. 6 The acetate buffer was prepared by dissolving 8.2 g of sodium acetate into 180 mL of water, followed by pH adjustment with acetic acid to 4.5 and filling up with water to a final volume of 200 mL. Stock solutions of cefepime (100 and 500 µg/mL for preparation of calibrators and controls, respectively) and ceftazidime (400 µg/mL, internal standard) were prepared in 10-fold diluted acetate buffer (pH 4.5) and stored as 0.2 mL aliquots at -70°C. The sample preparation reagent was composed of 75 mM SDS in acetate buffer, pH 4.5. For the preparation of calibrators, aliquots of 1.0, 5.0, 10.0, 20.0, 40.0, and 60.0 µL of the 100 µg/mL cefepime stock solution and aliquots of water (49.0, 45.0, 40.0, 30.0, 10.0, and 0 µL, respectively) were added to 100 µL of bovine serum and treated as described in Section 2.2.2.
Due to internal calibration with a constant amount of the internal standard, this procedure provided calibrators with 1.0, 5.0, 10.0, 20.0, 40.0, and 60.0 µg/mL cefepime, respectively. Three controls containing 6.0, 25.0, and 45.0 µg/mL cefepime in bovine serum were prepared batchwise. Typically, 3.5 mL of a control was produced by combining an appropriate amount of the 500 µg/mL cefepime stock solution with bovine serum and aliquots of 100 µL were frozen in plastic vials at −70°C. Frozen samples were slowly defrosted and vortex mixed before analysis.
Sample preparation
Sample preparation is based upon deproteination with SDS at pH 4.5. If not stated otherwise, 100 µL of sample (patient sample, control), 20 µL of internal standard solution, 50 µL of sample preparation reagent and 50 µL of water were combined in a 2.0 mL Eppendorf vial. After mixing, 250 µL of dichloromethane was added. The sample was mixed again for about 5 s and centrifuged at 13 000 × g for about 10 min at 20°C using a model Journal of Separation Science This article is protected by copyright. All rights reserved. 7 5415 R Eppendorf centrifuge (Hamburg, Germany). Then, 100 µL of the clear supernatant was transferred into a PCR sample vial for analysis. Calibrators were treated the same way except that no water was added before centrifugation.
Instrumentation and running conditions
MEKC analyses were performed in uncoated fused-silica capillaries of 50 µm id (Polymicro Technologies, Phoenix, AZ, USA) and 60 cm (50 cm effective) length using a P/ACE MDQ and a PA800plus CE system (Beckman Coulter, Brea, CA, USA). The BGE (separation medium) was composed of 6 mM Na 2 B 4 O 7 , 10 mM Na 2 HPO 4 , and 75 mM SDS (pH 9.1) and is the same as employed previously [5] . Analyses were carried out with an applied voltage of 15 kV (current: 23.5 µA), analyte detection using the UV detector at 254 nm, and hydrodynamic sample injection during 6 s at 1 psi (1 psi = 6894.8 Pa). To increase the performance, a short water plug was injected after the sample (3 s at 0.5 psi). The temperatures of capillary cartridge and sample holder were maintained at 25 and 25°C, respectively. Quantitation was based upon six-point internal calibration in the range of 1.0 to 60.0 g/mL of cefepime using corrected peak areas (peak areas divided by detection time) for data evaluation. Other conditions as reported previously [5] .
LC-ESI-MS assay
Solutions, calibrators and controls
Stock solutions of cefepime (500, 10 and 1 µg/mL), deuterated cefepime (10 µg/mL) and ceftazidime (100 µg/mL) were prepared in 50 mM acetic acid and stored as small aliquots Journal of Separation Science This article is protected by copyright. All rights reserved. 
Sample preparation
Sample preparation was based on deproteination with acetonitrile. Fifty microliters of sample (patient sample, control), 10 µL of internal standard solution, 50 µL of 50 mM acetic acid and 125 µL of acetonitrile were combined in a 2.0 mL Eppendorf vial, vortexed for about 15 s and centrifuged at 13 000 x g for 5 min at 20°C. After centrifugation, 125 µL of the clear supernatant was transferred to another Eppendorf vial and combined with 250 µL of water. After mixing for 10 s, 125 µL of dichloromethane was added. Sample was mixed and centrifuged again. Then, 100 µL of the upper aqueous layer was transferred into the LC-MS vial and analyzed. Calibrators were treated the same way, except that no acetic acid was added before centrifugation.
Instrumentation and running conditions
series 1100 (Hewlett Packard, Waldbronn, Germany) coupled to a Agilent 6120 Single Quadrupole LC-MS System with an APCI/ESI interface (Agilent Technologies, Santa Clara, California). A gradient elution was applied with solvent A, containing 5 mM ammonium formate (pH 3.0), and solvent B comprising 100% acetonitrile. The mobile phase flow rate was maintained at 0.5 mL/min. Solvent B was increased from 5 to 20% in the time range of 0-10 min (linear gradient). Thereafter, the column was rinsed for 2 min with 50% of solvent B at a flow rate of 2 mL/min. Re-equilibration was performed during 3 min at the same flow rate with 5% B. The column oven temperature was set to 25°C and the injection volume was 10 µL. Nitrogen, provided by a nitrogen generator N2-Mistral-4 (Schmidlin Labor, Neuheim, Switzerland), was used as nebulizing and desolvation gas. The flow rate of nitrogen was 10 L/min, drying temperature was 300°C and nebulizing pressure was 60 psig. Quantitation was based upon seven-point internal calibration in the range of 0.25 to 10.0 g/mL of cefepime using peak areas for data evaluation.
Determination of recovery
To determine the recovery of cefepime and the internal standard, spiked samples in water and bovine serum were analyzed and the recovery was calculated as the mean ratio between the Journal of Separation Science This article is protected by copyright. All rights reserved. 10 peak area response of three or four replicates of these samples and the corresponding peak area response of equivalent samples in water.
Statistical and graphical data analysis
Data evaluation and presentation was made with SigmaPlot software version 12.5 (Systat Software, San Jose, CA, USA). The Mann-Whitney rank sum test was used to compare two groups of data. P < 0.05 was considered to be significant.
Results and discussion
MEKC analysis of cefepime in presence of sulfamethoxazole
With our routine MEKC assay, comigration of cefepime with sulfamethoxazole, one of the two active compounds present in co-trimoxazole (sulfamethoxazole and trimethoprim), was observed [5] . An example of the interference is presented with the electropherogram depicted in Fig. 1A . The data represent the analysis of a serum of a patient who received both cefepime and co-trimoxazole. Initial efforts to separate cefepime and sulfamethoxazole by modification of the BGE composition were not successful. Thus, efforts with different sample preparations were investigated to solve this problem. Cefepime and ceftazidime are hydrophilic compounds (for chemical structures see inserts in Figs. 1A and 1C, respectively; logP ow values of about -2.7 [17] ). Sulfamethoxazole is more hydrophobic than cefepime and ceftazidime (for chemical structure see insert in Fig. 1E ; logP ow value of 0.89 [18] ). Thus, dichloromethane was added to the mixture of serum and sample preparation reagent (for composition of sample preparation reagent see Ref. [5] ). After µg/mL was calculated. This is much less compared to the value obtained when the entire peak of Fig. 1A is used for quantification (123.9 µg/mL). These data illustrate that a further modification of the sample preparation was required for proper MEKC analysis of cefepime in such a sample.
A change in the preparation of the acetate buffer for the sample preparation reagent provided the anticipated breakthrough. For the assay described previously [5] , the acetate buffer was made from a 0.5 M acetic acid to which 0.5 M sodium acetate solution was added until pH 4.5 was obtained (estimated buffer composition: 0.500 M acetic acid and 0.177 M NaOH). In the work described here, the acetate buffer was prepared with a 0.500 M sodium acetate solution whose pH was adjusted with acetic acid to 4.5 (Section 2.2.1, estimated composition of 1.413 M acetic acid and 0.500 M NaOH). Using this buffer with about 2.8-fold higher concentration in the sample preparation reagent, resolution between cefepime and sulfamethoxazole became possible. This is illustrated with the analysis of the same patient sample for which a small cefepime peak of 3.8 µg/mL was now detected before a large sulfamethoxazole peak (Fig. 1C ). Furthermore, the small peak detected before the internal standard (marked with # in panels A and C of Fig. 1 ) could not be separated from the internal standard (Fig. 1C ). The small peak is an impurity of ceftazidime used as internal standard and was not detected under the conditions of Fig. 1A when the internal standard was omitted. Finally, sample preparation with extraction of sulfamethoxazole with dichloromethane as described in Section 2.2.2 provided the data of Fig. 1D . Comparison with panel C reveals the same amount of cefepime (4.1 µg/mL) and a much reduced peak of sulfamethoxazole and the peak marked with an asterisk were monitored in the aqueous phase. These data visualize that dichloromethane does not completely remove sulfamethoxazole. Analysis of the organic phase provided two peaks (insert in Fig. 1D ) which is comparable to the analysis with the previous sample matrix (insert in Fig. 1B ).
Furthermore, spiking of the aqueous phase of Fig. 1D with cefepime and reanalysis resulted in a much enlarged sharp peak for cefepime ( Fig. 1E) . Thus, the sample matrix change associated with the acetate buffer in the sample preparation reagent led to the separation Journal of Separation Science This article is protected by copyright. All rights reserved. 13 of cefepime and sulfamethoxazole and the use of dichloromethane removed a large portion of sulfamethoxazole from the sample. Both effects were combined in the modified MEKC assay and referred to as MEKC-DCM in the remaining part of this paper. Characterization of the modified assay with data comparison to those obtained with the routine MEKC method is described below. It is important to note, that BGE composition, sample injection and applied voltage were kept the same as in the previous assay [5] . No efforts were undertaken to investigate the reasons for the impact of acetate buffer composition on the MEKC separation of cefepime and sulfamethoxazole.
MEKC assay characterization with dichloromethane removal of interferences
With the new sample preparation, internal standard and cefepime were detected around 9 and 11 min, respectively, and the current was about 24 µA, values that are comparable to those under the previous assay conditions [5] . Electropherograms obtained with the three Table 1 summarizes the analytical characteristics of the six-level internal calibration for 6 consecutive sets of data. The calibration graphs were found to be linear (r 2  0.9991) with F values  4360 (P < 0.001). Mean values for the slope and r 2 were 0.0110 mL/µg and 0.9995, respectively. Furthermore, the mean of the y intercept was -0.0044, a value which is significantly smaller than the ratio produced by the smallest calibrator. The recovery This article is protected by copyright. All rights reserved. 14 assessed for cefepime levels of 5 and 60 g/mL were determined to be 105.7 and 98.4%, respectively. Corresponding values for ceftazidime were 108.9 and 98.8%, respectively. The limit for quantitation was taken as 1 g/mL (smallest calibrator) and the detection limit was determined to be 0.5 g/mL (S/N=3). Typical assay imprecision data for detection times and drug levels obtained for the analysis of the three control samples are summarized in Table 2 .
Intraday and interday (n=6) RSD values for the detection times were < 0.7 and < 1.6%, respectively. Intraday and interday drug level repeatabilities were found to be  3.1 and  5.5%, respectively. All these data compare favorably with those obtained previously [5] and illustrate that the MEKC-DCM assay is robust and suitable for TDM. Analysis of human plasma with EDTA as anticoagulant instead of human serum resulted in indistinguishable electropherograms. Thus, plasma patient samples were analyzed with the same assay.
Comparison of cefepime levels determined with the two MEKC methods for 128 patient samples whose electropherograms did not exhibit apparent interferences with cefepime shows excellent agreement between the two assays. Evaluation with the Mann-Whitney rank sum test revealed no statistically significant difference between the two input groups (P = 0.701). Linear regression analysis of the 128 data pairs revealed a linear relationship (r 2 = 0.941) described by the equation MEKC = 0.94 x MEKC-DCM + 0.47 which is very close the line of equality (Fig. 3A) . Plotting the difference of the two values (MEKC -MEKC-DCM) against the mean shows excellent consistency between the two methods (Fig. 3B) . The mean of the differences and SD were -0.80 and 3.25 g/mL, respectively, indicating that on average the MEKC-DCM method gave slightly higher amounts than the assay without the respectively. Comparison of the two sets of data with the Mann-Whitney rank sum test revealed no statistically significant difference between the two input groups (P = 0.451).
Thus, for the given set of samples, the data obtained with MEKC-DCM and MEKC could be validated by LC-MS.
Results with samples of patients receiving co-trimoxazole and other potential interferences
With our previous MEKC assay [5] , a number of samples could not be analyzed due to interferences, including those associated with sulfamethoxazole ( Fig. 1 ). If not carefully investigated by peak shape analysis as described previously [5] , the use of this assay could lead to unrealistic cefepime levels as is shown with the data of samples 1 to 6 presented in Fig. 6A . The determined cefepime levels (MEKC data of Fig. 6A ) are much higher compared to those monitored with the modified sample preparation (MEKC-DCM data). The correctness of the latter cefepime levels could be confirmed by LC-MS (Fig. 6A ). MEKC-DCM and LC-MS analysis of samples from patients that received both cefepime and cotrimoxazole revealed cefepime levels that compare well (Fig. 6B ). For the 38 samples whose data are presented in Fig. 6B , linear regression analysis of the data pairs revealed a linear relationship with a coefficient of determination r 2 of 0.988, a slope of 1.02 and a y intercept of 0.42 µg/mL. This is very close to a line of equality. Furthermore, comparison of the two sets of data with the Mann-Whitney rank sum test revealed no statistically significant difference between the two input groups (P = 0.975). It is interesting to note that the second compound extracted with dichloromethane (panels B and D of Fig. 1 
) was found in Journal of Separation Science
This article is protected by copyright. All rights reserved. 18 all 38 samples. This suggests that it represents a metabolite of sulfamethoxazole. These data demonstrate that the MEKC-DCM assay is suitable to properly handle patient samples that contain sulfamethoxazole.
Furthermore, it is important to mention that compounds other than sulfamethoxazole, which are not hydrophobic and are thus not removed by dichloromethane but are detected in proximity of cefepime or the internal standard, may still produce interferences. Analysis of critical samples by MEKC-DCM, including those of Fig. 4 in [5] , however, was straightforward. Cefepime levels determined by MEKC-DCM were found to compare well with those obtained with LC-MS. Drug levels of two examples, whose electropherograms are presented in Fig. 6C , are presented as samples 7 and 8 in Fig. 6A . These two samples stem from critically ill patients that received multiple drugs. Sample 7 is the patient serum whose data are presented in Fig. 4B of the previous paper [5] for which cefepime was detected at the front edge of a broad interference of unknown identity (graph a of Fig. 6C ).
With the MEKC-DCM assay cefepime could be detected interference-free whereas resolution between the internal standard and a broad peak detected shortly thereafter was diminished ( Fig. 6C, compare graphs a and b) . The cefepime level determined was almost identical to that obtained with LC-MS and somewhat higher than that measured by MEKC ( Fig. 6A) . Similar results were obtained with sample 8 (Fig. 6A , upper graphs in Fig. 6C ). It is important to note that the complexity of these electropherograms is not observed frequently. Typically, very few peaks other than those of cefepime and the internal standard are monitored ( Fig. 2D ; examples given in [5] ). Thus, to avoid interferences with Journal of Separation Science This article is protected by copyright. All rights reserved. 19 sulfamethoxazole and other neutral compounds, the previously described MEKC assay should be replaced with the MEKC-DCM method described in this paper. With MEKC-DCM, analysis of both the sample and the same sample fortified with a small amount of cefepime is also recommended to verify peak assignment (for examples see Ref. [5] ). Fig. 6A (graphs a and b , respectively) and sample 8 of Fig. 6A (graphs c and d, respectively). a) The assigned concentration values and ratios of corrected peak areas (cefepime/IST) were taken as x-axis and y-axis values, respectively. b) Interday calibration from 6 consecutive sets of data. 
a)
